INVESTOR LOGIN
06 March 2017 |

EryDel announces start of ATTEST, Pivotal Phase III Trial in Ataxia Telangiectasia

EryDel SpA, a biopharmaceutical company specialized in the development of drugs and diagnostics delivered through autologous red blood cells, today announced the initiation of the Ataxia Telangiectasia Trial with the EryDex System (ATTEST) study, a pivotal Phase 3 trial to evaluate the efficacy, safety and tolerability of EDS in patients with A-T